A cholecystokinin agonist/antagonist according to dose and time of action: Effect on food intake
Neuropeptides, ISSN: 0143-4179, Vol: 17, Issue: 4, Page: 187-191
1990
- 3Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures3
- Readers3
Article Description
A new CCK pseudopeptide (Boc-Tyr (SO 3 )-Nle-ψ-(COCH 2 ) Gly-Trp-Nle-Asp-Phe-NH 2 ) has been described in a previous study as a potent CCK agonist in the peripheral system and as an antagonist in the central nervous sytem. When administered alone by a peripheral route, this pseudopeptide was found to decrease food intake in free/feeding rats, and thus behaved as a CCK agonist. However, it reversed the decreased feeding effect induced by a full potent agonist (Boc(Nle 28-Nle 31)-CCK26-33). This antagonistic action occurred 3–4h after treatment, at a time when the agonistic properties of the pseudopeptide alone had disappeared, but when the effect of the full potent agonist remained. The dose-response curve of the antagonistic action was bell-shaped. These results suggest that this new pseudopeptide is not only agonistic in the periphery and antagonistic in the central nervous system as shown in the previous study, but is also both agonistic and antagonistic on the same paradigm according to the dose and time of action.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/014341799090034V; http://dx.doi.org/10.1016/0143-4179(90)90034-v; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0025651911&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/2093151; http://linkinghub.elsevier.com/retrieve/pii/014341799090034V; http://api.elsevier.com/content/article/PII:014341799090034V?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:014341799090034V?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/014341799090034V; http://dx.doi.org/10.1016/0143-4179%2890%2990034-v; https://dx.doi.org/10.1016/0143-4179%2890%2990034-v
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know